Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users (Q28284151)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520602%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

title

Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520602%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520602%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

author name string

K A Schoedel

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520602%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

D Meier

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520602%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

B Chakraborty

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520602%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

P M Manniche

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520602%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

language of work or name

English

0 references

publication date

2 June 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520602%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

4 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520602%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

volume

88

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520602%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520602%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

page(s)

69-78

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520602%20AND%20SRC:MED&resulttype=core&format=json

Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease

4 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038/CLPT.2010.67

Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/CLPT.2010.67

Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/CLPT.2010.67

Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/CLPT.2010.67

Pharmacokinetic Determinants of Drug Abuse and Dependence

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/CLPT.2010.67

Comparison of the effects of sibutramine and other weight-modifying drugs on extracellular dopamine in the nucleus accumbens of freely moving rats

21 April 2017

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.67

Abuse liability assessment of atomoxetine in a drug-abusing population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.67

Sibutramine: a new weight loss agent without evidence of the abuse potential associated with amphetamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.67

Abuse liability assessment of sibutramine, a novel weight control agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.67

Postmarketing surveillance for drug abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.67

Postmarketing surveillance of abuse liability of sibutramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.67

Pharmacokinetic considerations in abuse liability evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.67

Serum and brain concentrations of methylphenidate: implications for use and abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.67

Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.67

Variables That Affect the Clinical Use and Abuse of Methylphenidate in the Treatment of ADHD

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.67

Effect of intravenous injection speed on responses to cocaine and hydromorphone in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.67

The rate of intravenous cocaine administration alters c-fos mRNA expression and the temporal dynamics of dopamine, but not glutamate, overflow in the striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.67

The rate of cocaine administration alters gene regulation and behavioral plasticity: implications for addiction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.67

Rapid delivery of nicotine promotes behavioral sensitization and alters its neurobiological impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.67

Why does the rapid delivery of drugs to the brain promote addiction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.67

Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.67

PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.67

Stimulant medications: how to minimize their reinforcing effects?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.67

Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: results from imaging studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.67

Discriminative stimulus effects of d-amphetamine, methylphenidate, and diazepam in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.67

A comparison of bupropion, dextroamphetamine, and placebo in mixed-substance abusers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.67

The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.67

Principles of initial experimental drug abuse liability assessment in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.67

Assessing abuse liability during drug development: changing standards and expectations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.67

Human abuse liability of the smoking cessation drug varenicline in smokers and nonsmokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.67

Do Formulation Differences Alter Abuse Liability of Methylphenidate?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.67

7 January 2021

Mechanism of action of methylphenidate: insights from PET imaging studies

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.67

7 January 2021

Research design strategies to evaluate the impact of formulations on abuse liability

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.67

7 January 2021

Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.67

7 January 2021

Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.67

7 January 2021

Identifiers

DOI

10.1038/CLPT.2010.67

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520602%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference